JP2023526283A5 - - Google Patents

Info

Publication number
JP2023526283A5
JP2023526283A5 JP2022569035A JP2022569035A JP2023526283A5 JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5 JP 2022569035 A JP2022569035 A JP 2022569035A JP 2022569035 A JP2022569035 A JP 2022569035A JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5
Authority
JP
Japan
Prior art keywords
cancer
unsubstituted
substituted
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526283A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032094 external-priority patent/WO2021231653A1/en
Publication of JP2023526283A publication Critical patent/JP2023526283A/ja
Publication of JP2023526283A5 publication Critical patent/JP2023526283A5/ja
Priority to JP2026033895A priority Critical patent/JP2026083268A/ja
Pending legal-status Critical Current

Links

JP2022569035A 2020-05-15 2021-05-12 単独療法及び併用療法 Pending JP2023526283A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026033895A JP2026083268A (ja) 2020-05-15 2026-03-04 単独療法及び併用療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063025490P 2020-05-15 2020-05-15
US63/025,490 2020-05-15
US202063040832P 2020-06-18 2020-06-18
US63/040,832 2020-06-18
US202063089419P 2020-10-08 2020-10-08
US63/089,419 2020-10-08
US202163160325P 2021-03-12 2021-03-12
US63/160,325 2021-03-12
US202163161828P 2021-03-16 2021-03-16
US63/161,828 2021-03-16
PCT/US2021/032094 WO2021231653A1 (en) 2020-05-15 2021-05-12 Mono- and combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026033895A Division JP2026083268A (ja) 2020-05-15 2026-03-04 単独療法及び併用療法

Publications (2)

Publication Number Publication Date
JP2023526283A JP2023526283A (ja) 2023-06-21
JP2023526283A5 true JP2023526283A5 (cg-RX-API-DMAC7.html) 2024-05-17

Family

ID=78525230

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022569035A Pending JP2023526283A (ja) 2020-05-15 2021-05-12 単独療法及び併用療法
JP2026033895A Pending JP2026083268A (ja) 2020-05-15 2026-03-04 単独療法及び併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026033895A Pending JP2026083268A (ja) 2020-05-15 2026-03-04 単独療法及び併用療法

Country Status (12)

Country Link
US (1) US20230210854A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153594A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023526283A (cg-RX-API-DMAC7.html)
KR (1) KR20230010729A (cg-RX-API-DMAC7.html)
CN (1) CN115867551A (cg-RX-API-DMAC7.html)
AU (1) AU2021271844A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023254A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182270A1 (cg-RX-API-DMAC7.html)
IL (1) IL298201A (cg-RX-API-DMAC7.html)
MX (1) MX2022014131A (cg-RX-API-DMAC7.html)
TW (1) TWI906299B (cg-RX-API-DMAC7.html)
WO (1) WO2021231653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2023147297A2 (en) * 2022-01-25 2023-08-03 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2024102650A1 (en) * 2022-11-08 2024-05-16 Zeno Management, Inc. Intermittent dosing regimen for azenosertib in treating cancer
TW202502354A (zh) * 2023-06-02 2025-01-16 美商薩諾管理公司 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy
WO2025226653A1 (en) * 2024-04-23 2025-10-30 Zeno Management, Inc. Wee1 inhibitor combination therapy dosing regimen
WO2025245463A1 (en) * 2024-05-23 2025-11-27 Merck Patent Gmbh Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043945A1 (en) * 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用

Similar Documents

Publication Publication Date Title
Sørensen et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
RU2757373C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2020525427A5 (cg-RX-API-DMAC7.html)
JP2021102627A5 (cg-RX-API-DMAC7.html)
JP2024516997A5 (cg-RX-API-DMAC7.html)
ES2426938T3 (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos
RU2010117635A (ru) Комбинированная химиотерапия
JP2021510376A5 (cg-RX-API-DMAC7.html)
JP2023508332A5 (cg-RX-API-DMAC7.html)
JP2012523435A5 (cg-RX-API-DMAC7.html)
JP2023508328A5 (cg-RX-API-DMAC7.html)
JP2013542241A5 (cg-RX-API-DMAC7.html)
JP2018525358A5 (cg-RX-API-DMAC7.html)
JP2024147816A (ja) がん治療における免疫モジュレーションのための組合せ
JP2022521818A5 (cg-RX-API-DMAC7.html)
JP2021522197A5 (cg-RX-API-DMAC7.html)
JP2025503971A5 (cg-RX-API-DMAC7.html)
US20190240210A1 (en) Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP2023507797A5 (cg-RX-API-DMAC7.html)
AU2019271151A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
JP2026506429A (ja) Mta協同的prmt5阻害薬を使用した癌治療
JP2022533211A (ja) 小細胞肺がんの併用療法用キノリン誘導体
Mir-Bonafé et al. Adverse hair reactions to new targeted therapies for cancer
AU2023375870A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
IL278721B1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma